Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BGenBio
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BGenBio
-
Prikvačeni tweet
BerGenBio ASA presents its results for the second quarter and first half 2019. Read the full release here: http://bit.ly/2z8fNVq pic.twitter.com/FPFLyJc7MM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we mark
#WorldCancerDay
2020 to honor the millions of people worldwide who have been affected by cancer #WCD20pic.twitter.com/CxHwRnS18oHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you,
@ASH_hematology, for organising yet another encouraging and insightful conference.#bemcentinib#AXLinhibitor#ASH19 See you again next year!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The presentation of updates from our Phase II trial with
#bemcentinib in combination with LDAC in elderly AML patients will be starting at 6pm in Hall B – come find us there!#ASH19#AXLinhibitorHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re pleased to be attending the 61st
@ASH_hematology conference this weekend! We will be presenting the latest data from our Phase II trial with#bemcentinib in combination with LDAC in elderly AML patients on today at 6pm#ASH19#AXLinhibitorpic.twitter.com/dxib7iXMAy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Many thanks to the organisers for a fantastic
#SITC2019. We’ve enjoyed a packed schedule and the opportunity to connect with friends old and new. See you next time!#NSCLC#bemcentinib#AXLinhibitorHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BerGenBio presents latest data from Cohort A of the Phase II combination trial of
#bemcentinib and#keytruda in#NSCLC. Come find us at the High Impact Clinical Trials session at the Prince George’s Exhibition Hall C at 5.10pm. https://prn.to/2Q0lLl8#AXLinhibitor#SITC2019pic.twitter.com/j9Onne6NJ0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@OfficialUoM’s Dr Matthew Krebs will be presenting the final data readout of the first cohort our Phase II trial of#bemcentinib and#keytruda in advanced#NSCLC. Come along to the High Impact Clinical Trials session this afternoon.#AXLinhibitor#SITC2019pic.twitter.com/tRKnI1mP7v
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you
#ESMO19 for a great conference and to all the attendees that made so worthwhile. See you again in 2020!#NSCLC#bemcentinib#AXLinhibitor#skcsmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Straume is presenting a poster on our Phase Ib/II trial with
#bemcentinib in combination with#dabrafenib/trametinib or#pembrolizumab in patients with metastatic melanoma. Presentation kicks off at 12pm in the poster area, Hall 4!#ESMO19#skcsm#bemcentinib#AXLinhibitorpic.twitter.com/RmdGAYf8Ey
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At 12pm, Dr Jose M. Trigo Perez will present details of our Phase II trial of
#bemcentinib and#keytruda in patients with advanced#NSCLC. Come find us in the poster area, Hall 4. https://bit.ly/2mbCYeS#ESMO19#AXLinhibitorpic.twitter.com/H8rwL55C5x
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we are presenting Phase II Trial Updates with Selective
#AXLinhibitor#bemcentinib at the 2019 ESMO Congress. Come see us in the poster area, Hall 4 at 12 pm! https://bit.ly/2mbCYeS#ESMO19#AXLinhibitor#NSCLCpic.twitter.com/xK3aPNVbAT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We look forward to attending
#ESMO19 over the next few days in Barcelona! We will be presenting trial updates from our Phase II studies with selective#AXLinhibitor#bemcentinib. See you soon!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you
#WCLC2019 for another outstanding conference this year, we look forward to the next one#NSCLC#bemcentinib#AXLinhibitorpic.twitter.com/U1p5HKoqgM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BerGenBio's CEO Richard Godfrey to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference today. Full details are on our website here: http://bit.ly/2m9B8ux
#bemcentinib#AXLinhibitor#NSCLC#AMLpic.twitter.com/ZiCYaudEAN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Enriqueta Felip presented a Mini Oral Session today at
#WCLC2019 on our#Phase2 trial with#bemcentinib and#keytruda in patients with#NSCLC following chemotherapy#AXLinhibitor http://bit.ly/2k5ZQv4 pic.twitter.com/9tLPAi3OHc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Enriqueta Felip presents a Mini Oral Session today in Colorado Springs (1994) at 11:05am on our
#Phase2 trial with#bemcentinib and#keytruda in patients with#NSCLC following chemotherapy#WCLC2019#AXLinhibitorpic.twitter.com/NEohebHdnp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BerGenBio presents update of its Phase II trial of selective AXL inhibitor
#bemcentinib in#NSCLC at 2019 World Conference on Lung Cancer http://bit.ly/2k0Kxnm pic.twitter.com/zSUSO5h6t7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re looking forward to this year’s World Conference on Lung Cancer kicking off tomorrow. See you in Barcelona!
#WCLC2019#NSCLC#bemcentinib#AXLinhibitorpic.twitter.com/Z50gRmOA3Y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BerGenBio proslijedio/la je Tweet
Read our Lighthouse note on
@BGenBio at https://www.trinitydelta.org/companies/bergenbio/ …, which covers the company's H119 results and the refinements to the clinical programme for its lead asset bemcentinib, the selective AXL inhibitor.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.